A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1, significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial — the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares — show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.